Association of SCD* and CDAI (OR and 95% CI estimated using logistic regression)
CDAI | Unadjusted | Model 1 | Model 2 | Model 3* | Model 4* | Model 5* | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
Remission | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
Low | 2.69 | 2.35–3.09 | 2.21 | 1.92–2.54 | 2.17 | 1.88–2.50 | 1.96 | 1.70–2.26 | 1.25 | 1.08–1.45 | 1.22 | 1.05–1.42 |
Moderate | 4.78 | 4.17–5.49 | 3.41 | 2.96–3.92 | 3.25 | 2.81–3.75 | 2.78 | 2.41–3.22 | 1.53 | 1.31–1.78 | 1.46 | 1.25–1.71 |
Severe | 6.53 | 5.66–7.53 | 4.08 | 3.52–4.74 | 3.83 | 3.29–4.47 | 3.19 | 2.72–3.73 | 1.50 | 1.26–1.77 | 1.42 | 1.20–1.69 |
Exploratory analysis: model 1: age, insurance, BMI, education, race, disabled, smoking status, duration of RA, history of diabetes, history of fibromyalgia, exercising, and drinking; model 2: model 1 + prednisone use, NSAIDs use, narcotic use, number prior biologics, current MTX use, and current biologic/TS DMARDs use; model 3: model 2 + patient-reported depression; model 4: model 2 + patient fatigue; model 5: model 2 + patient-reported depression and patient fatigue. * SCD determined with patient self-report of difficulty thinking and confusion. Ref: OR = 1